GlassScriptPhysician profile
Abdel Kader Tal
NPI 1972708105
$3,154.65
in general payments reported to CMS, 2019-2025
18 companies · $719 in 2025
The $719 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $138 · 2021: $148 · 2022: $531 · 2023: $509 · 2024: $581 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,809.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $613.49 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $410.60 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $320.64 | 2019-2024 | Tremfya |
| Pfizer INC. | $281.77 | 2022-2025 | |
| Galderma Laboratories, L.P. | $259.16 | 2019-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $227.59 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $153.25 | 2022-2025 | Adbry |
| Dermavant Sciences, INC. | $150.11 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $138.25 | 2021-2024 | Tremfya, Simponi Aria, Stelara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.56 | 2024 | Spevigo |
| Lilly USA, LLC | $114.56 | 2023-2024 | Taltz, Olumiant |
| Genzyme Corporation | $94.88 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $76.72 | 2023 | Dupixent |
| Sun Pharmaceutical Industries INC. | $50.86 | 2022-2025 | Ilumya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.05 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $43.45 | 2019-2021 | |
| Ucb, INC. | $32.90 | 2025 | Bimzelx |
| Almirall LLC | $16.81 | 2023 | Seysara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdel Kader Tal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.